Author/Authors :
Ejtehadi ، Fardad Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Farahvashi ، Paymun Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Shamsaeefar ، Alireza Shiraz Organ Transplant Center - Shiraz University of Medical Sciences , Niknam ، Ramin Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Sivandzadeh ، Gholam Reza Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Aminlari ، Ladan Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Motazedian ، Nasrin Shiraz Transplant Research Center - Shiraz University of Medical Sciences , Kazemi ، Kourosh Shiraz Organ Transplant Center - Shiraz University of Medical Sciences , Nikoupour ، Hamed Shiraz Organ Transplant Center - Shiraz University of Medical Sciences , Nikeghbalian ، Saman Shiraz Organ Transplant Center - Shiraz University of Medical Sciences , Eghlimi ، Hesameddin Shiraz Organ Transplant Center - Shiraz University of Medical Sciences , Taghavi ، Alireza Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Fattahi ، Mohammadreza Gastroenterohepatology Research Center - Shiraz University of Medical Sciences , Bagheri Lankarani ، Kamran Health Policy Research Center, Institute of Health - Shiraz University of Medical Sciences , Malek-Hosseini ، Ali Shiraz Organ Transplant Center - Shiraz University of Medical Sciences
Abstract :
Background: Hepatitis C is one of the most common causes of end-stage liver disease and liver transplant worldwide. In recent years, with the rapid advances in the treatment of hepatitis C by direct-acting antiviral drugs (DAAs), the clinical course of the disease as well as liver transplantation have had significant improvement. Also, DAAs have completely replaced interferon-based regimens in the treatment and prevention of HCV recurrence after liver transplant. Objectives: This is the first study that aimed to investigate the clinical course of liver transplantation in patients with hepatitis C in Iran. Methods: This retrospective study was conducted on patients with HCV liver transplantation within five years (2012-2017) with the age range of 18 to 65 years at Shiraz Organ Transplant Center. All demographic and clinical data were recorded. Pre-transplant viral load, disease recurrence, graft rejection, and mortality rate were the most important indices in this study. Results: Among 55 transplant patients, 49% had received hepatitis C treatment before liver transplantation and interferonbased regimens were more prevalent. Besides, HCV genotype 3, followed by genotype 1, was the most prevalent one. A liver biopsy was performed in patients with elevated liver enzyme levels. The numbers of patients with HCV recurrence at 2, 6, 12, and 24-month intervals were three, two, zero, and two patients, respectively. At these time intervals, eight, eight, one, and three cases of acute graft rejection were found, respectively. Eight patients died with a one-year survival rate of 85%. Sepsis and infectious complications were the most leading causes of death. Conclusions: This study is the first study of liver transplant patients with hepatitis C in Iran. In the five-year study period, rapid development was made in the treatment of HCV patients. It led to the introduction of DAAs, which replaced interferon-based therapies. The results of this study indicated the high success rate of liver transplantation in patients with hepatitis C in Iran. The results of this study could be used to compare the efficacy of DAAs in future research.
